PINNED
PINNED
Endotoxin testing milestone reached with European Pharmacopoeia’s animal shift
The quality control (QC) standards publication sets animal-free bacterial endotoxins testing (BET) as the new norm in Europe.
List view / Grid view
News
New malaria target identified with potential to prevent, block, and treat multiple stages of the malaria life cycle
28 November 2013 | By Novartis
Novartis scientists have discovered a new drug target for treating malaria...
GSK receives positive CHMP opinion for Cervarix™ two-dose schedule
28 November 2013 | By GlaxoSmithKline
GSK announced that the European Medicines Agency's Committee for Medicinal Products for Human Use is recommending marketing authorisation for a two-dose schedule in 9-14 year old girls for its cervical cancer vaccine, Cervarix™...
Mettler-Toledo to present live webinar entitled “Ensuring USP Compliance with Revised Chapters on Weighing”
27 November 2013 | By Mettler Toledo
Mettler-Toledo announced an upcoming webinar entitled “Ensuring USP Compliance with Revised Chapters on Weighing" with special guest presenter Mr. Gregory Martin, President of Complectors Consulting LLC...
Building a case of precision pipetting with Tecan’s Air LiHa
26 November 2013 | By kdm communications limited
Complementing the laboratory’s existing liquid displacement Freedom EVO platforms for DNA extraction, this new instrument will help to streamline the workflow and improve pipetting precision...
Hepatitis C: Boehringer Ingelheim’s faldaprevir granted accelerated assessment from European Medicines Agency
26 November 2013 | By Boehringer Ingelheim
The application for European marketing authorisation of faldaprevir* has been fully validated and granted accelerated assessment by the European Medicines Agency...
Cubist announces positive top-line results from phase 3 trial of investigational antibiotic ceftolozane/tazobactam…
25 November 2013 | By Cubist
“We are very pleased with these positive results, which represent a significant milestone for both ceftolozane/tazobactam and Cubist...”
Sanofi and Regeneron’s Dupilumab named “Clinical Advance of the Year” by Scrip Intelligence
25 November 2013 | By Sanofi
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Phase 2a study of dupilumab in asthma was named "Clinical Advance of the Year" by Scrip Intelligence at the 9th annual Scrip Awards. The award was announced last week by Scrip, a leading pharmaceutical…
Teva comments on recent article
25 November 2013 | By TEVA
Teva Pharmaceutical Industries Ltd. issued the following statement regarding an article published by The Marker...
GSK Responds to FDA decision on Avandia (rosiglitazone)
25 November 2013 | By GlaxoSmithKline
The U.S. Food and Drug Administration has eased restrictions on patient access to Avandia (rosiglitazone)...
H5N1 vaccine approved by the U.S. FDA as pandemic influenza preparedness measure
25 November 2013 | By GlaxoSmithKline
GlaxoSmithKline plc announced that the FDA has approved its pandemic Influenza A Virus Monovalent Vaccine...
Novo Nordisk and Roche Diabetes Care are joining forces to make insulin pump therapy simpler for people with diabetes
22 November 2013 | By Novo Nordisk
Insulin aspart PumpCart® is a 1.6 ml prefilled insulin pump cartridge containing the rapid-acting insulin aspart...
OLYSIO™ (simeprevir) receives FDA approval for combination treatment of chronic hepatitis C
22 November 2013 | By Johnson & Johnson
OLYSIO™ works by blocking the viral protease enzyme that enables the hepatitis C virus (HCV) to replicate in host cells...
CHMP determines Dimethyl Fumarate in TECFIDERA® to be a new active substance in the European Union
22 November 2013 | By Biogen Idec
This designation will provide 10 years of regulatory exclusivity for TECFIDERA in the European Union...
Xigduo™ receives positive CHMP opinion in the European Union for the treatment of type 2 diabetes
22 November 2013 | By AstraZeneca
Xigduo™ combines dapagliflozin (tradename Forxiga®), a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2), and metformin hydrochloride in a twice daily tablet...
U.S. FDA Approves NEXAVAR® (sorafenib) for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment
22 November 2013 | By Amgen
First and only FDA-approved treatment option for patients with this type of thyroid cancer...
